The Epigenetic Promise to Improve Prognosis of Heart Failure and Heart Transplantation
Heart transplantation (HT) remains the gold standard treatment for end-stage heart failure (HF) ensuring the highest long-term survival; however, due to the shortage of organ donors, the left ventricular assist device (LVAD) provides a backup strategy for patients as bridge to transplantation or when clinical contraindications are present [1,2]. HF represents the end-stage of several cardiac pathological conditions including atherosclerosis, coronary heart disease (CHD) and dilated, hypertrophic and restrictive cardiomyopathies [3-5].
Source: Transplantation Reviews - Category: Transplant Surgery Authors: Chiara Sabia, Antonietta Picascia, Vincenzo Grimaldi, Cristiano Amarelli, Ciro Maiello, Claudio Napoli Tags: Review article Source Type: research
More News: Cardiology | Coronary Heart Disease | Heart | Heart Disease | Heart Failure | Heart Transplant | Transplant Surgery | Transplants